-$0.70 Earnings Per Share Expected for Tricida, Inc. (NASDAQ:TCDA) This Quarter

Brokerages forecast that Tricida, Inc. (NASDAQ:TCDA) will announce earnings of ($0.70) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Tricida’s earnings, with estimates ranging from ($0.78) to ($0.62). Tricida posted earnings per share of ($1.55) in the same quarter last year, which would suggest a positive year over year growth rate of 54.8%. The company is expected to announce its next quarterly earnings report on Monday, November 8th.

On average, analysts expect that Tricida will report full year earnings of ($3.10) per share for the current fiscal year, with EPS estimates ranging from ($3.20) to ($3.00). For the next year, analysts expect that the firm will report earnings of ($2.54) per share, with EPS estimates ranging from ($3.12) to ($1.95). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Tricida.

Tricida (NASDAQ:TCDA) last issued its earnings results on Monday, August 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.17.

Separately, Needham & Company LLC started coverage on shares of Tricida in a research report on Tuesday, August 10th. They issued a “buy” rating and a $20.00 target price for the company.

Several large investors have recently modified their holdings of TCDA. Point72 Asset Management L.P. raised its stake in Tricida by 81.4% in the second quarter. Point72 Asset Management L.P. now owns 4,814,949 shares of the company’s stock worth $20,801,000 after buying an additional 2,160,588 shares in the last quarter. BlackRock Inc. raised its stake in Tricida by 8.3% in the first quarter. BlackRock Inc. now owns 2,714,638 shares of the company’s stock worth $14,360,000 after buying an additional 208,872 shares in the last quarter. Great Point Partners LLC raised its stake in Tricida by 464.6% in the second quarter. Great Point Partners LLC now owns 1,974,000 shares of the company’s stock worth $8,528,000 after buying an additional 1,624,400 shares in the last quarter. Morgan Stanley raised its stake in Tricida by 18.3% in the second quarter. Morgan Stanley now owns 1,727,196 shares of the company’s stock worth $7,461,000 after buying an additional 267,335 shares in the last quarter. Finally, FMR LLC raised its stake in Tricida by 9.7% in the first quarter. FMR LLC now owns 1,213,065 shares of the company’s stock worth $46,849,000 after buying an additional 107,500 shares in the last quarter. 65.20% of the stock is owned by hedge funds and other institutional investors.

Shares of TCDA traded down $0.04 during mid-day trading on Friday, reaching $4.43. 110,801 shares of the stock traded hands, compared to its average volume of 454,446. The firm has a fifty day moving average price of $4.14 and a 200 day moving average price of $4.52. The company has a market cap of $223.40 million, a price-to-earnings ratio of -1.01 and a beta of 1.34. The company has a current ratio of 7.28, a quick ratio of 7.28 and a debt-to-equity ratio of 3.52. Tricida has a 1 year low of $3.55 and a 1 year high of $9.81.

Tricida Company Profile

Tricida, Inc is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.

Read More: How does the Federal Reserve determine interest rates?

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.